Antidepressant drug-drug interaction profile update

Drugs in R and D

Volumn 6, Issue 6, 2005, Pages 323-336

  Ereshefsky, Larry ^a,b,d   Jhee, Stanford ^b   Grothe, Dale ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b CALIFORNIA CLINICAL TRIALS   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; CODEINE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DESVENLAFAXINE; DEXTROMETHORPHAN; DIPHENHYDRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYDROCODONE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORFLUOXETINE; PAROXETINE; PSYCHOTROPIC AGENT; REBOXETINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; COMORBIDITY; DELIRIUM; DEPRESSION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; HUMAN; LONG TERM EXPOSURE; PAIN; PARALYTIC ILEUS; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; STEADY STATE; TOXICITY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION; DRUG INTERACTIONS; HUMANS; METABOLIC CLEARANCE RATE;

EID: 27744576368     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200506060-00002     Document Type: Review

References (70)

1. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000; 12 Suppl. 1: 30-44
2. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000 Jan 38; (1): 41-57
3. Chang WH, Augustin B, Lane HY, et al. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacol (Berl) 1999; 145 (1): 91-8
4. Armstrong SC, Stephans JR. Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage [letter]. J Clin Psychiatry 1997; 58 (11): 499
5. Wang CY, Zhang ZJ, Li WB, et al. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 2004; 44 (7): 785-92
6. Bootman JL. The $76 billion wake-up call. J Am Pharm Assoc (Wash) 1996 Jan; NS36 (1): 27-8
7. Johnson JA, Bootman JL. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am J Health Syst Pharm 1997 Mar 1; 54 (5): 554-8
8. Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 1996; 44 (8): 944-8
9. Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Institute of Medicine. Washington, DC: National Academy Press, 1999
10. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997 Jan 22; 277 (4): 301-6
11. Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001 Sep; 9 (6): 442-51
12. Ereshefsky L. Antidepressant drug interaction considerations. Manag Care 2001 Aug; 10 (8 Suppl.): 10-3
13. US Food and Drug Administration. Guidance for industry pharmacogenomic data submissions [online]. Available from URL: http://www.fda.gov/cder/guidance/ 6400nfl.htm [Ac-cessed 2005 Aug 31]
14. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19 (4): 299-320
15. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33 (1): 67-74
16. Richelson E. Pharmacokinetic drug interactions of new anti-depressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72 (9): 835-47
17. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996 Mar; 153 (3): 311-20
18. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996; 16 (3 Suppl. 2): 37S-50S
19. Sindrup SH, Hofmann U, Asmussen J, et al. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. Eur J Clin Pharmacol 2005; 49 (6): 503-9
20. Mikus G, Morike K, Griese EU, et al. Relevance of deficient CYP2D6 in opiate dependence. Pharmacogenetics 1998 Dec; 8 (6): 565-8
21. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997 Oct; 7 (5): 375-9
22. Dalen P, Dahl ML, Ruiz ML, et al. 10-Hydroxylation of nor-triptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63 (4): 444-52
23. Lam YW, Gaedigk A, Ereshefsky L, et al. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achieva-ble steady-state plasma concentrations and the effect of ul-trarapid metabolism at CYP2D6. Pharmacotherapy 2002 Aug; 22 (8): 1001-6
24. Ereshefsky L. Antidepressant pharmacodynamics, pharmaco-kinetics, and drug interactions. Geriatrics 1998; 53 Suppl. 4: 22-33
25. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol 2001; 41: 815-50
26. Shu Y, Cheng ZN, Liu ZQ, et al. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol Sin 2001 Mar; 22 (3): 283-8
27. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7 Suppl. 1: 11-7
28. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000; 61 Suppl. 2: 20-5
29. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003; 73 (3): 170-7
30. Burke WJ. Escitalopram. Expert Opin Investig Drugs 2002; 11 (10): 1477-86
31. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7 (3): 249-64
32. Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram: a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000 May; 25 (3): 241-54
33. Caccia S. Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs 2004 Feb; 7 (2): 143-50
34. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000 Oct; 28 (10): 1176-83
35. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Es-citalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001 Aug; 29 (8): 1102-9
36. Clinically relevant drug interaction table. Indiana University Department of Medicine, Division of Clinical Pharmacology 2004 [online]. Available from URL: http://medicine.iupui.edu/flockhart/clinlist.htm [Accessed 2004; August 3]
37. Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992; 33 (5): 521-3
38. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280 (2): 927-33
39. Ring BJ, Eckstein JA, Gillespie JS, et al. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine. J Pharmacol Exp Ther 2001; 297 (3): 1044-50
40. Carrillo JA, Dahl ML, Svensson JO, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60 (2): 183-90
41. Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999; 27 (7): 763-6
42. Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am 2000 Jan; 9 (1): 43-76
43. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol 2001 April; 21 (2): 161-6
44. Bostwick JM. Dextromethorphan-induced manic symptoms in a bipolar patient on lithium. Psychosomatics 1996 Nov; 37 (6): 571-3
45. Clovis WL. Mania and cough syrup [letter]. J Clin Psychiatry 1993 May; 54 (5): 200
46. Mendez MF. Mania self-induced with cough syrup. J Clin Psychiatry 1992 May; 53 (5): 173-4
47. Polles A, Griffith JL. Dextromethorphan-induced mania. Psychosomatics 1996 Jan; 37 (1): 71-4
48. Schadel M, Romach MK, Sellers EM. Mania and cough syrup [letter]. J Clin Psychiatry 1993 May; 54 (5): 200
49. Howard LA, Sellers EM, Tyndale RF. The role of pharmacogenetically- variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 2002 Mar; 3 (2): 185-99
50. Kennedy SH, McCann SM, Masellis M, et al. Combining bupro-pion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002 Mar; 63 (3): 181-6
51. Alfaro CL, Lam YW, Simpson J, et al. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a cross-over study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000; 40 (1): 58-66
52. Amchin J, Ereshefsky L, Zarycranski W, et al. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol 2001; 41 (4): 443-51
53. Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996 Feb; 41 (2): 149-56
54. Effexor XR [package insert]. Collegeville (PA): Wyeth Pharmaceuticals, 2004
55. Cymbalta [package insert]. Indianapolis (IN): Eli Lilly and Company, 2004
56. Prozac [package insert]. Indianapolis (IN): Eli Lilly and Company, 2003
57. Zoloft [package insert]. New York (NY): Pfizer Laboratories, 2003
58. Paxil [package insert]. Research Triangle Park (NC): Glaxo-SmithKline, 2002
59. Lexapro [package insert]. St Louis (MO): Forest Laboratories, 2003
60. Celexa [package insert]. St Louis (MO): Forest Laboratories, 2004
61. Luvox [package insert]. Marietta (GA): Solvay Pharmaceuticals, 2001
62. Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 2002 Jun; 17 Suppl. 1: S25-35
63. Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003 Oct; 13 (10): 619-26
64. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003 Oct; 17 (5): 517-38
65. Wienkers LC, Allievi C, Hauer MJ, et al. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999; 27 (11): 1334-40
66. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000; 39 (6): 413-27
67. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000; 40 (2): 161-7
68. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91
69. Mancama D, Kerwin RW. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 2003; 17 (3): 143-51
70. Serretti A, Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 2004; 4 (4): 233-44